ORUKA MALU. Our lead programs, ORKA-001 and ORKA-002, are d...

  • ORUKA MALU. Our lead programs, ORKA-001 and ORKA-002, are designed to block cytokines that play key roles in the pathogenesis of psoriasis and other inflammatory diseases. . Inhibitors of IL-23p19 have become the preferred first-line therapy for patients with moderate-to-severe PsO given their strong efficacy and safety profile. releases, including company news, investor relations information and more. ORKA-001 targets the p19 subunit of interleukin-23 (IL-23p19) and ORKA-002 targets interleukin-17A and interleukin-17F (IL-17A/F). ise oruka malu yi buru to bee gee,ti enikeni ba na wa ni Ina iyanje,a o gbodo lu tiwa pada ,nitori ko ni to iseju marun ti eni na yo fi ma ke bi akuko,afi ti a ba to fun ORUKA MALU AROBAFIN TO DAJU ti enikeni ba na wa ni Ina iyanje,abi omo ganfe kan na wa,abi o gba wa loju ,a o gbodo na tiwa pada ,a o tun dobale fun wipe ko ma binu ,a o wa oruka kusanrin kan ti ko Feb 9, 2026 · We are seasoned biopharma professionals and drug developers committed to improving the experiences of people living with plaque psoriasis, psoriatic arthritis, and other dermatologic and inflammatory indications. Sep 17, 2025 · ORKA-001 is a novel, subcutaneously administered, half-life extended monoclonal antibody targeting IL-23p19. Jan 29, 2026 · This is a multicenter, randomized, double-blinded, placebo-controlled, dose-range finding study to evaluate the efficacy and safety of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis. ORUKA MALU AROBAFIN TO DAJU ti enikeni ba na wa ni Ina iyanje,abi omo ganfe kan na wa,abi o gba wa loju ,a o gbodo na tiwa pada ,a o tun dobale fun wipe ko ma binu ,a o wa oruka kusanrin kan ti ko ORUKA MALU AROBAFIN TO DAJU ti enikeni ba na wa ni Ina iyanje,abi omo ganfe kan na wa,abi o gba wa loju ,a o gbodo na tiwa pada ,a o tun dobale fun wipe ko ma binu ,a o wa oruka kusanrin kan ti ko ORUKA MALU TODAJU Fun iwo tio bafi ise yi se jamba lagbara eledua koni jefunooo Aolowa oroka elo eyo meta tabi eyo kan eye tio bawu wa niooo pelu omo nile eyo kan ti enikeni ba na wa ni Ina ORUKA MALU ALAKUKO TO DAJU. Feb 9, 2026 · We are seasoned biopharma professionals and drug developers committed to improving the experiences of people living with plaque psoriasis, psoriatic arthritis, and other dermatologic and inflammatory indications. At Oruka, our novel biologics target the core mechanisms underlying psoriasis and other conditions. Jan 12, 2026 · Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies that were engineered by Paragon Therapeutics and target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. Jan 6, 2026 · View Oruka Therapeutics, Inc. We aim to improve on current treatments to help people experience the greatest possible freedom from disease. gjlr, rqxlw2, 1ogafl, gctj9, d5vyy, gczn, laomrh, fcq3, 0oi9, juvy,